Myasthenia gravis: The pharmacological basis of traditional Chinese medicine for its clinical application.

Publisher: Ios Press Country of Publication: Netherlands NLM ID: 8807441 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8081 (Electronic) Linking ISSN: 09516433 NLM ISO Abbreviation: Biofactors Subsets: MEDLINE

Publication: Amsterdam : Ios Press
Original Publication: Oxford ; Washington, DC : Published for the International Union of Biochemistry by IRL Press, [c1988-

Drugs, Chinese Herbal*/pharmacology ; Drugs, Chinese Herbal*/therapeutic use ; Myasthenia Gravis*/drug therapy ; Myasthenia Gravis*/genetics; Follow-Up Studies ; Humans ; Medicine, Chinese Traditional ; Molecular Docking Simulation

We aimed to investigate the target and signal pathway of Smilacis Glabrae Rhixoma (SGR) in the treatment of myasthenia gravis (MG) based on network pharmacology, and to explore its potential molecular mechanism. The main active components of SGR were searched in the pharmacology database of traditional Chinese medicine systems, and analysis platform. The related targets of SGR were obtained by Genecards, connective tissue disease, therapeutic target database, Drugbank, and Online Mendelian Inheritance in Man database. Moreover, the target information was corrected through UniProtKB and also, this data integrated to draw the "Ingredients-targets" network of SGR. Protein interaction analysis was performed in data platform, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways as well as enrichment analysis on disease-drug target was carried out through metascape online platform. A total of 15 active components were collected from SGR, which correspond to 159 targets; There were 1758 MG-related targets; there are 81 targets related to both drug components and diseases, including 12 key targets. In GO bioaccumulation analysis, 1933 GO items were gathered, which were mainly related to the metabolism of active oxygen species and the active factors of postsynaptic neurotransmitter receptor. According to KEGG analysis, SGR may play a role in the treatment of MG through phosphatidylinositol-3-kinase-protein kinase B signaling pathway, T-cell receptor, cAMP, tumor necrosis factor (TNF), and interleukin-17 (IL-17) signaling pathway, Th17 cell differentiation, endocrine resistance, hepatitis, and some cancer pathways. This study shows that SGR mainly treat myasthenia gravis through the regulation of TNF, MAPK1, JUN, TP53 and other targets, T-cell receptor, TNF, and IL-17 signaling pathway, Th17 cell differentiation and other pathways, which reflects the characteristics of multicomponent, multitarget, and multichannel of traditional Chinese medicine, and providing a certain pharmacological basis for the follow-up study.
(© 2021 International Union of Biochemistry and Molecular Biology.)

Ting C. Guidelines for diagnosis and treatment of myasthenia gravis in China (2020 edition). Chin J Neuroimmunol Neurol. 2021;28:1-12.
Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.
Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009;73:150-1.
García Estévez DA, López Díaz LM, Pardo Parrado M, Pérez Lorenzo G, Sabbagh Casado NA, Ozaita Arteche G, et al. Epidemiology of myasthenia gravis in the province of Ourense (Galicia, Spain). Neurologia. 2020. https://doi.org/10.1016/j.nrl.2020.06.011. Online ahead of print.
Stojanov A, Milošević V, Đorđević G, Stojanov J. Quality of life of myasthenia gravis patients in regard to epidemiological and clinical characteristics of the disease. Neurologist. 2019;24:115-20.
Liu C, Li T, Wang Q, Xu A, Wu B. Post-traumatic stress disorder symptoms after respiratory insufficiency in patients with myasthenia gravis. Psychol Health Med. 2021;26:221-7.
Sun Y, Li J. Li Jiageng's experience in treating myasthenia gravis. Hubei J Tradit Chin Med. 2014;36:30.
Lulu C, Bingquan W, Chaoyuan C, Qinghe L, Qinghe L. Experience in treating myasthenia gravis by eliminating dampness and detoxifying. Western J Tradit Chin Med. 2021;34:34-6.
Xiong J, Qiansong H, Shixiang K. Introduction of Kuang Shixiang's clinical experience in treating myasthenia gravis from "toxin". Jiangsu J Tradit Chin Med. 2016;48:19-21.
Jianhui L, Shixiang K. Treating myasthenia gravis from damp poison [a]. Neurology professional Committee of Guizhou Association of integrated traditional Chinese and Western medicine. Papers compilation of the sixth annual conference of neurology of integrated traditional Chinese and Western medicine in Guizhou Province [C]. Neurology professional Committee of Guizhou Association of integrated traditional Chinese and Western medicine: Guizhou Association of Integrated Traditional Chinese and Western Medicine, 2013: 3.
Chen T, Li JX, Xu Q. Phenylpropanoid glycosides from Smilax glabra. Phytochemistry. 2000;53:1051-5.
Guangyao C, Liansheng S, Peifen J. Study on chemical constituents of Smilacis Glabrae Rhixoma. J Beijing Uni Tradit Chin Med. 1996;19:44.
Shuang C, Caiying P, Lingling P, Jian L, Shengjia C, Jicheng S. Modern research Progress of traditional Chinese medicine, Smilacis Glabrae Rhixoma. Jiangxi J Tradit Chin Med. 2021;52:69-76.
Meng QF, Zhang Z, Wang YJ, Chen W, Li FF, Yue LT, et al. Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells. J Neuroimmunol. 2016;298:138-45.
Jinlong R. Construction and application of pharmacology database and analysis platform of traditional Chinese medicine system. Xianyang: Northwest A&F University; 2015.
Safran M, Dalah I, Alexander J. GeneCards version 3: the human gene integrator. Database. 2010;2010:q20.
Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: online Mendelian inheritance in man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015;43:D789-98.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074-82.
Xiaoni Y, Guoxiang T, Hairong H, Xiaomin L, Jun Z, Jun L. CTD database architecture and data acquisition query and extraction method. Chin J Evid-Based Cardiovasc Med. 2019;11:905-9.
Chen X, Ji ZL, Chen YZ. TTD: therapeutic target database. Nucleic Acids Res. 2002;30:412-5.
Xueying J, Li G, Wei Z. Research progress on etiology and pathogenesis of myasthenia gravis. Chin J Cell Mol Immunol. 2021;37:368-72.
Xu F, Cui W, Kong Q, Tang Z, Dong J. A real-world evidence study for distribution of traditional Chinese medicine syndrome and its elements on respiratory disease. Evid-Based Complementary Altern Med. 2018;2018:8305892.
Dong FH. Precise application of traditional Chinese medicine in minimally-invasive techniques. Zhongguo Gu Shang. 2018;31:493-6.
Dashtdar M, Dashtdar MR, Dashtdar B, Kardi K, Shirazi MK. The concept of wind in traditional Chinese medicine. J Pharmacopuncture. 2016;19:293-302.
Jing X, Shan G, Lin L. Research progress and application strategy of network pharmacology in the field of traditional Chinese medicine. Chin Tradit Herbal Drug. 2019;50:2257-65.
Kailing X, Yifan Z. Research Progress of regulatory T cells in myasthenia gravis. J Apoplexy Nervous Dis. 2020;37:1141-3.
Pandey A, Negi PS. Traditional uses, phytochemistry and pharmacological properties of Neolamarckia cadamba: a review. J Ethnopharmacol. 2016;181:118-35.
Liao PC, Lai MH, Hsu KP, Kuo YH, Chen J, Tsai MC, et al. Identification of β-sitosterol as in vitro anti-inflammatory constituent in Moringa oleifera. J Agric Food Chem. 2018;66:10748-59.
Ding K, Tan YY, Ding Y, Fang Y, Yang X, Fang J, et al. β-Sitosterol improves experimental colitis in mice with a target against pathogenic bacteria. J Cell Biochem. 2019;120:5687-94.
Chen Y, Tang YM, Yu SL, Han YW, Kou JP, Liu BL, et al. Advances in the pharmacological activities and mechanisms of diosgenin. Chin J Nat Med. 2015;13:578-87.
Shuai W, Yu S, Chunmei L, Qun L. Overview of research progress of stigmasterol. China Pharmaceutical. 2019;28:96-8.
Çebi M, Durmus H, Aysal F, Özkan B, Gül GE, Çakar A, et al. CD4+ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS. Front Immunol. 2020;11:809.
Liu W. Therapeutic effect of diosgenin in experimental autoimmune encephalomyelitis model. Anhui University. 2018.
Atay O, Skotheim JM. Spatial and temporal signal processing and decision making by MAPK pathways. J Cell Biol. 2017;216:317-30.
Patel K, Gadewar M, Tahilyani V, Patel DK. A review on pharmacological and analytical aspects of diosmetin: a concise report. Chin J Integr Med. 2013;19:792-800.
Ying Y, Yunyun W, Qichen J. Research progress on pharmacological effects of quercetin. Spec Econ Animal Plant. 2020;23:24-8.
Wang L, Gao F, Lin G, Yuan Y, Huang Y, Hao H, et al. Association of hepatitis E virus infection and myasthenia gravis: a pilot study. J Hepatol. 2018;68:1318-20.
Yang CW, Lee YZ, Hsu HY, Wu CM, Chang HY, Chao YS, et al. C-Jun-mediated anticancer mechanisms of tylophorine. Carcinogenesis. 2013;34:1304-14.
Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 2013;7:57-68.
Doss GP, Agoramoorthy G, Chakraborty C. TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory diseases. Front Biosci. 2014;19:1028-40.
Minli Y, Shulong D. Advances in molecular genetics of gallbladder carcinoma. World Chin J Digestol. 2019;27:903-6.
Guanghui W, Hong M, Zhengxin R, Chuanyu L, Qinxiu Z. Study on the expression and correlation of proto-oncogene C-Jun in nasal mucosa inflammatory cells of rats with allergic rhinitis. J Clin Otorhinolaryngol. 2003;8:478-80.
Kohler S, Keil TOP, Hoffmann S, Swierzy M, Ismail M, Rückert JC, et al. CD4+ FoxP3+ T regulatory cell subsets in myasthenia gravis patients. Clin Immunol. 2017;179:40-6.
Souroujon MC, Aricha R, Feferman T, Mizrachi K, Reuveni D, Fuchs S. Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci. 2012;1274:120-6.
Masuda M, Matsumoto M, Tanaka S, Nakajima K, Yamada N, Ido N, et al. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol. 2010;225:123-31.
Mangodt TC, Van Herck MA, Nullens S, Ramet J, De Dooy JJ, Jorens PG, et al. The role of Th17 and Treg responses in the pathogenesis of RSV infection. Pediatr Res. 2015;78:483-91.
Hashemi SA, Kyani A, Bathaie SZ. The in silico mechanism of hVKOR interaction with acetaminophen and its metabolite, as well as N-acetyl cysteine: caution on application in COVID-19 patients. J Biomol Struct Dyn. 2021;1-12. https://doi.org/10.1080/07391102.2021.1910570. Online ahead of print.
Salemizadeh Parizi M, Salemizadeh Parizi F, Abdolhosseini S, Vanaei S, Manzouri A, Ebrahimzadeh F. Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies. Inflammopharmacology. 2021;29:1613-1624. https://doi.org/10.1007/s10787-021-00878-9.
Cuthbertson CR, Arabzada Z, Bankhead A, Kyani A, Neamati N. A review of small-molecule inhibitors of one-carbon enzymes: SHMT2 and MTHFD2 in the spotlight. ACS Pharmacol Transl Sci. 2021;4:624-46.
Nourbakhsh E, Mohammadi A, Salemizadeh Parizi M, Mansouri A, Ebrahimzadeh F. Role of myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target. Inflammopharmacology. 2021;29:1307-15.
Cuthbertson CR, Guo H, Kyani A, Madak JT, Arabzada Z, Neamati N. The dihydroorotate dehydrogenase inhibitor brequinar is synergistic with ENT1/2 inhibitors. ACS Pharmacol Transl Sci. 2020;3:1242-52.

Keywords: Smilacis Glabrae Rhixoma; myasthenia gravis; network; pharmacological

0 (Drugs, Chinese Herbal)

Date Created: 20211218 Date Completed: 20220316 Latest Revision: 20220316

20250114

10.1002/biof.1812

34921710